Multicenter clinical outcomes of hole implantable collamer lens implantation in middle-aged patients

Sci Rep. 2022 Mar 10;12(1):4236. doi: 10.1038/s41598-022-08298-7.


To assess the multicenter clinical outcomes of the implantation of hole implantable collamer lens (Hole ICL, ICL KS-AquaPORTTM; STAAR Surgical, Nidau, Switzerland) in patients of 45 years or more. We retrospectively assessed the surgery's safety, efficacy, predictability, stability, and adverse events before surgery and after the surgery at 1 week; 1, 3, and 6 months; and 1 year, followed by once every year for approximately 2.2 years. A total of 118 eyes of 65 patients aged 45-65 years with myopic refractive errors ranging from - 2.13 to - 18.75 diopters (D) underwent hole ICL implantation and routine postoperative examinations. The average observation period was 2.2 ± 1.0 years. The safety and efficacy indices were 1.08 ± 0.21 and 0.87 ± 0.25, respectively. Manifest refraction changes of - 0.20 ± 0.43 D occurred from 1 month to the final visit after ICL implantation. Eight eyes (6.8%) developed asymptomatic anterior subcapsular cataract (ASC) immediately after surgery, and three eyes (2.5%) developed clinically significant symptomatic nuclear cataracts during the follow-up period. According to our experience, hole ICL implantation offered favorable outcomes in all measures of safety, efficacy, predictability, and stability, even in middle-aged patients, during the 2.2-year observation period.

Publication types

  • Multicenter Study

MeSH terms

  • Follow-Up Studies
  • Humans
  • Lens Implantation, Intraocular / adverse effects
  • Lenses, Intraocular*
  • Middle Aged
  • Phakic Intraocular Lenses*
  • Refraction, Ocular
  • Retrospective Studies
  • Treatment Outcome
  • Visual Acuity